Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Top Page
Acumen Pharmaceuticals
(NASDAQ:ABOS)
Rating:36Underperform
Price Target:―
Positive Factors
Financial Position
ABOS finished 2024 with $231.5M in cash and cash equivalents, sufficient to fund operations into 1H27.
Trial Enrollment
Completion of enrollment of ALTITUDE AD indicates an overall enthusiasm for a differentiated anti Abeta immunotherapy despite the availability of two drugs in the market.
Negative Factors
Market Impact
The stock continues to suffer due to the meaningful wait for the next key readout.
Price Target
The reevaluation of opex assumption going forward reduces the price target to $11 from $15.
Acumen Pharmaceuticals (ABOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$61.78M
Dividend YieldN/A
Average Volume (3M)213.55K
Price to Earnings (P/E)―
Beta (1Y)2.50
Revenue GrowthN/A
EPS Growth-57.45%
CountryUS
Employees61
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding60,573,425
10 Day Avg. Volume214,010
30 Day Avg. Volume213,551
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.33Price Target Upside716.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Acumen Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
How the Company Makes MoneyAcumen Pharmaceuticals generates revenue primarily through funding from investors, partnerships, and collaborations rather than traditional product sales, as it is still in the clinical trial phase. The company relies on strategic alliances with pharmaceutical companies, research institutions, and government grants to support its research and development activities. Additionally, Acumen may receive milestone payments and royalties from potential future licensing agreements for its drug candidates, contingent upon successful clinical development and regulatory approval.
Acumen Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q1-2025)
| % Change Since: -2.86%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call for Acumen Pharmaceuticals demonstrates significant progress and innovation in their Alzheimer’s treatment development, particularly with the rapid enrollment and innovative biomarker use in their ALTITUDE-AD study, as well as promising results in subcutaneous administration. Despite increased R&D expenses and operating losses, the company's strong financial position and strategic advancements indicate a generally positive outlook.Q1-2025 Updates
Positive Updates
Rapid Enrollment in ALTITUDE-AD Phase 2 Study
Completed enrollment of the 542-participant ALTITUDE-AD Phase 2 study in roughly 10 months, much faster than expected, attributed to the interest in Sabirnetug’s therapeutic potential and innovative participant screening methods.
Innovative Use of Plasma Biomarkers
Used plasma phospho-tau 217 screening to improve enrollment efficiency in ALTITUDE-AD, resulting in 81% of screened individuals testing positive on amyloid PET, compared to 40% in a previous study.
Presentations at Major Alzheimer's Conferences
Presented at ADPD and AAN conferences, highlighting innovative methods in Alzheimer’s drug development, including insights into synaptic biomarkers and A-beta oligomer selective assays.
Progress in Subcutaneous Administration
Completed a Phase 1 study comparing subcutaneous and intravenous administration of Sabirnetug, showing it was well-tolerated with systemic exposure supporting continued development.
Strong Financial Position
Held $197.9 million in cash and marketable securities, expected to support clinical and operational activities into early 2027.
Negative Updates
Increased R&D Expenses
R&D expenses increased to $25.3 million in Q1 2025, primarily due to spending on the ALTITUDE-AD trial.
Operating Loss Reported
Reported a loss from operations of $30.4 million and a net loss of $28.8 million for the quarter.
Company Guidance
During the Acumen Pharmaceuticals Q1 2025 conference call, the company provided guidance on several key metrics and developments. Acumen completed enrollment of their Phase 2 study, ALTITUDE-AD, with 542 participants in just 10 months, significantly faster than expected. This study aims to evaluate the efficacy and safety of Sabirnetug, their next-generation treatment for early Alzheimer's disease, with topline results anticipated in late 2026. Financially, Acumen reported $197.9 million in cash and marketable securities as of March 31, 2025, projecting this to support operations into early 2027. R&D expenses for the quarter were $25.3 million, primarily driven by ALTITUDE-AD trial costs, while G&A expenses remained steady at $5.1 million. This resulted in a loss from operations of $30.4 million and a net loss of $28.8 million for the quarter. The company also highlighted their innovative use of fluid biomarkers, particularly plasma p-tau 217, which significantly improved screening efficiency, reducing negative PET scans from 60% to 19%.Acumen Pharmaceuticals Financial Statement Overview
Summary
Acumen Pharmaceuticals faces significant financial challenges with no revenue generation and mounting losses. The balance sheet is stable with no debt, but declining assets could pose future liquidity risks. Cash flow issues are prominent, with heavy reliance on financing activities to support operations.Income Statement
Acumen Pharmaceuticals' income statement shows a persistent lack of revenue generation, with total revenues standing at zero for the past four years. The company has been experiencing substantial net losses, with a notable increase in net loss from $73.2 million in 2020 to $102.3 million in 2024. The absence of revenue combined with increasing operating losses highlights significant challenges in achieving profitability.15
Very Negative
Balance Sheet
The balance sheet reflects a stable equity base, with stockholders' equity exceeding liabilities, indicating a low risk of insolvency. However, the company has seen a decline in total assets from $310.1 million in 2023 to $239 million in 2024. The absence of debt provides financial flexibility, but the consistent decrease in asset base may indicate potential liquidity concerns.45
Neutral
Cash Flow
The cash flow statement reveals negative free cash flow over the years, with an increasing deficit from $43 million in 2023 to $86 million in 2024. Operating cash flow remains negative, highlighting ongoing challenges in generating cash from operations. Financing activities have been a critical source of cash, but reliance on external financing may not be sustainable long-term.30
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 290.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M | Gross Profit |
| 162.00K | 0.00 | -42.32M | -169.00K | -4.00K | 1.43M | EBIT |
| -92.91M | -114.02M | -61.14M | -45.24M | 61.57M | -7.91M | EBITDA |
| -75.48M | -114.02M | -51.61M | -42.69M | 61.58M | 587.00K | Net Income Common Stockholders |
| -81.67M | -102.33M | -52.37M | -40.48M | -181.68M | -7.32M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.55M | 171.56M | 243.52M | 177.60M | 194.24M | 43.78M | Total Assets |
| 0.00 | 238.99M | 310.13M | 196.59M | 230.33M | 44.43M | Total Debt |
| 0.00 | 0.00 | 28.49M | 105.00K | 0.00 | 0.00 | Net Debt |
| 6.55M | -35.63M | -38.40M | -130.00M | -122.16M | -43.78M | Total Liabilities |
| 0.00 | 57.18M | 43.15M | 7.81M | 5.15M | 63.02M | Stockholders Equity |
| 5.98M | 181.82M | 266.97M | 188.78M | 225.18M | -18.59M |
| Cash Flow | Free Cash Flow | ||||
| -67.34M | -86.23M | -43.09M | -35.31M | -18.00M | -7.45M | Operating Cash Flow |
| -67.31M | -86.22M | -43.06M | -35.15M | -17.96M | -7.45M | Investing Cash Flow |
| -30.44M | 48.03M | -171.67M | 39.19M | -104.12M | 0.00 | Financing Cash Flow |
| 36.07M | 6.93M | 151.75M | 3.91M | 200.47M | 44.67M |
Acumen Pharmaceuticals Technical Analysis
Negative
1.02
Price Trends
1.07
Negative
1.28
Negative
1.88
Negative
Market Momentum
-0.01
Negative
46.63
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Negative. The current price of 1.02 is below the 20-day moving average (MA) of 1.04, below the 50-day MA of 1.07, and below the 200-day MA of 1.88, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.63 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABOS.
Acumen Pharmaceuticals Risk Analysis
Acumen Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Acumen Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Q3, 2024
Acumen Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
44 Neutral | $89.79M | ― | -122.69% | ― | ― | 20.91% | |
42 Neutral | $107.69M | ― | -133.65% | ― | 148.33% | 42.41% | |
36 Underperform | $61.78M | ― | -55.68% | ― | ― | -57.45% | |
| $69.16M | ― | -20.33% | ― | ― | ― | ||
32 Underperform | $35.49M | ― | -1372.59% | ― | ― | 20.85% | |
| $79.93M | ― | -54.30% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
ABOS
Acumen Pharmaceuticals
1.02
-2.23
-68.62%
MNOV
Medicinova
1.43
0.11
8.33%
ASMB
Assembly Biosciences
14.10
-0.97
-6.44%
RANI
Rani Therapeutics Holdings
0.62
-3.98
-86.52%
IVVD
Invivyd
0.90
-0.86
-48.86%
GNTA
Genenta Science SpA Sponsored ADR
4.37
0.97
28.53%
Acumen Pharmaceuticals Corporate Events
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Acumen Pharmaceuticals Completes Enrollment for Phase 2 Study
Neutral
Mar 27, 2025
On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.